In various liver cancer cell lines exposed to high glucose conditions, CA inhibited the activity of cyclin-dependent kinase 19 (CDK19) that in turn reduced the Yes-associated protein (YAP)-O-GlcNAcylation pathway and thus decreased cancer cell proliferation and tumor growth [120]. The gene discussed is CDK19; the disease is liver cancer.